Pierre-FranÃ§ois Laterre

List of Publications by Year
in descending order

90 papers	12,047 citations	125106 35 h-index	53065 89 g-index
91 all docs	91 docs citations	91 times ranked	8657 citing authors

#	Article	IF	Citations
1	Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine, 2022, 77, 103893.	2.7	48
2	Pharmacokinetic profiles of intravenous versus subcutaneous administration of low molecular weight heparin for thromboprophylaxis in critically ill patients: A randomized controlled trial. Journal of Critical Care, 2022, 70, 154029.	1.0	2
3	Performance of the Cepheid Methicillin-Resistant Staphylococcus aureus/S. aureus Skin and Soft Tissue Infection PCR Assay on Respiratory Samples from Mechanically Ventilated Patients for S. aureus Screening during the Phase 2 Double-Blind SAATELLITE Study. Journal of Clinical Microbiology, 2022, 60, .	1.8	1
4	Acute Effects of Sitting Out of Bed and Exercise on Lung Aeration and Oxygenation in Critically Ill Subjects. Respiratory Care, 2021, 66, 253-262.	0.8	7
5	Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2021, 15, 149-157.	1.8	26
6	Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Critical Care, 2021, 25, 61.	2.5	25
7	Prone Positioning in Spontaneously Breathing Subjects With Moderate or Severe ARDS During Invasive Ventilation. Respiratory Care, 2021, 66, 724-732.	0.8	3
8	Serum uric acid, disease severity and outcomes in COVID-19. Critical Care, 2021, 25, 212.	2.5	22
9	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms, 2021, 9, 1543.	1.6	23
10	Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial. BMJ Open, 2021, 11, e042921.	0.8	12
11	COVID-19: an â€˜extraterrestrialâ€™ disease?. International Journal of Infectious Diseases, 2021, 110, 155-159.	1.5	3
12	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. BMC Infectious Diseases, 2021, 21, 1170.	1.3	46
13	Bioactive Adrenomedullin, Organ Support Therapies, and Survival in the Critically Ill. Critical Care Medicine, 2020, 48, 49-55.	0.4	13
14	A phase Ib/IIa, randomised, double-blind, multicentre trial to assess the safety and efficacy of expanded Cx611 allogeneic adipose-derived stem cells (eASCs) for the treatment of patients with community-acquired bacterial pneumonia admitted to the intensive care unit. BMC Pulmonary Medicine, 2020, 20, 309.	0.8	10
15	SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule. Kidney International, 2020, 98, 1296-1307.	2.6	173
16	New Agents in Development for Sepsis: Any Reason for Hope?. Drugs, 2020, 80, 1751-1761.	4.9	23
17	A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol. BMC Pulmonary Medicine, 2020, 20, 317.	0.8	12
18	Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial. Intensive Care Medicine, 2020, 46, 1425-1437.	3.9	38

#	Article	IF	Citations
19	The INHALE trial: multiple reasons for a negative result. Lancet Infectious Diseases, The, 2020, 20, 778-779.	4.6	12
20	The challenge of ventilator-associated pneumonia diagnosis in COVID-19 patients. Critical Care, 2020, 24, 289.	2.5	57
21	Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 822-829.	2.5	31
22	The IASIS, INHALE and VAPORISE trials. Reasons for a triple failure: Study design, aminoglycosides dosing and technique of nebulisation. Anaesthesia, Critical Care & Pain Medicine, 2020, 39, 179-183.	0.6	11
23	Immunotherapies for COVID-19: lessons learned from sepsis. Lancet Respiratory Medicine,the, 2020, 8, 946-949.	5.2	111
24	Selepressin for Patients With Septic Shockâ€"Reply. JAMA - Journal of the American Medical Association, 2020, 323, 667.	3.8	1
25	Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2019, 322, 1476.	3.8	107
26	Should we continue to test soluble thrombomodulin, or other systemic anticoagulants, as a life-saving therapy for sepsis-induced coagulopathy?. Anaesthesia, Critical Care & Pain Medicine, 2019, 38, 419-421.	0.6	1
27	Recommendations on the Diagnosis and Initial Management of Acute Variceal Bleeding and Hepatorenal Syndrome in Patients with Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 1419-1431.	1.1	9
28	CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised, trial. Lancet Infectious Diseases, The, 2019, 19, 620-630.	4.6	44
29	Passive leg cycling and electrical stimulation cannot preserve strength in sepsis. Critical Care, 2019, 23, 37.	2.5	1
30	A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2). BMJ Open, 2019, 9, e024475.	0.8	37
31	2160. Performance of the Cepheid Rapid PCR Test for Patient Screening and Association with Efficacy of Suvratoxumab, A Novel Anti-Staphylococcus aureus Monoclonal Antibody, During the Phase 2 SAATELLITE study. Open Forum Infectious Diseases, 2019, 6, S733-S733.	0.4	2
32	One-Year Prognosis of Kidney Injury at Discharge From the ICU: A Multicenter Observational Study. Critical Care Medicine, 2019, 47, e953-e961.	0.4	21
33	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. Journal of Antimicrobial Chemotherapy, 2019, 74, 1459-1461.	1.3	2
34	Open Lung Biopsy in Nonresolving Acute Respiratory Distress Syndrome Commonly Identifies Corticosteroid-Sensitive Pathologies, Associated With Better Outcome*. Critical Care Medicine, 2018, 46, 907-914.	0.4	21
35	Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shockâ€"Adaptive Clinical Trial. Annals of the American Thoracic Society, 2018, 15, 250-257.	1.5	31
36	Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Review of Gastroenterology and Hepatology, 2018, 12, 173-188.	1.4	16

#	Article	IF	Citations
37	Neutrophil-to-Lymphocyte Ratio Predicts Death in Acute-on-Chronic Liver Failure Patients Admitted to the Intensive Care Unit: A Retrospective Cohort Study. Shock, 2018, 49, 385-392.	1.0	40
38	Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study. Kidney International Reports, 2018, 3, 1424-1433.	0.4	53
39	Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Critical Care, 2018, 22, 354.	2.5	75
40	Pattern of Paracetamol Poisoning: Influence on Outcome and Complications. Toxics, 2018, 6, 58.	1.6	10
41	Safety and tolerability of a single administration of AR-301, a human monoclonal antibody, in ICU patients with severe pneumonia caused by Staphylococcus aureus: first-in-human trial. Intensive Care Medicine, 2018, 44, 1787-1796.	3.9	57
42	Impact of Very Early Physical Therapy During Septic Shock on Skeletal Muscle: A Randomized Controlled Trial. Critical Care Medicine, 2018, 46, 1436-1443.	0.4	74
43	Determinants of long-term outcome in ICU survivors: results from the FROG-ICU study. Critical Care, 2018, 22, 8.	2.5	123
44	A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Critical Care, 2017, 21, 22.	2.5	77
45	SPECT-CT Comparison of Lung Deposition using a System combining a Vibrating-mesh Nebulizer with a Valved Holding Chamber and a Conventional Jet Nebulizer: a Randomized Cross-over Study. Pharmaceutical Research, 2017, 34, 290-300.	1.7	59
46	Acute kidney injury in the ICU: from injury to recovery: reports from the 5th Paris International Conference. Annals of Intensive Care, 2017, 7, 49.	2.2	100
47	Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2017, 30, 349-358.	0.7	44
48	Epidural analgesia in critically ill patients with acute pancreatitis: the multicentre randomised controlled EPIPAN study protocol. BMJ Open, 2017, 7, e015280.	0.8	32
49	Aerosol delivery during invasive mechanical ventilation: a systematic review. Critical Care, 2017, 21, 264.	2.5	47
50	Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Critical Care, 2017, 21, 213.	2.5	93
51	Perspective on optimizing clinical trials in critical care: how to puzzle out recurrent failures. Journal of Intensive Care, 2016, 4, 67.	1.3	12
52	Teamwork enables high level of early mobilization in critically ill patients. Annals of Intensive Care, 2016, 6, 80.	2.2	61
53	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). World Journal of Emergency Surgery, 2016, 11, 33.	2.1	130
54	Changes in cardiac arrest patientsâ€™ temperature management after the 2013 â€œTTMâ€•trial: results from an international survey. Annals of Intensive Care, 2016, 6, 4.	2.2	71

#	Article	IF	Citations
55	Breakthrough in cardiac arrest: reports from the 4th Paris International Conference. Annals of Intensive Care, 2015, 5, 22.	2.2	27
56	Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients. Clinical Infectious Diseases, 2015, 60, 997-1006.	2.9	64
57	Prone positioning induced hepatic necrosis after liver transplantation. Intensive Care Medicine, 2015, 41, 1833-1833.	3.9	2
58	Early hyperlactatemia predicts pancreatic fistula after surgery. BMC Anesthesiology, 2015, 15, 109.	0.7	12
59	Influence of Inspiratory Flow Pattern and Nebulizer Position on Aerosol Delivery with a Vibrating-Mesh Nebulizer During Invasive Mechanical Ventilation: Anin VitroAnalysis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 229-236.	0.7	36
60	Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration. Journal of Antimicrobial Chemotherapy, 2015, 70, 891-898.	1.3	71
61	Myeloid-related protein-8/14 facilitates bacterial growth during pneumococcal pneumonia. Thorax, 2014, 69, 1034-1042.	2.7	36
62	Tracking the foreign body, a rare cause of hepatic abscess. BMC Gastroenterology, 2014, 14, 167.	0.8	18
63	Current practices and barriers impairing physiciansâ€™ and nursesâ€™ adherence to analgo-sedation recommendations in the intensive care unit - a national survey. Critical Care, 2014, 18, 655.	2.5	55
64	Energy expenditure in the critically ill performing early physical therapy. Intensive Care Medicine, 2014, 40, 548-555.	3.9	52
65	What stops us from following sedation recommendations in intensive care units? A multicentric qualitative study. Journal of Critical Care, 2014, 29, 291-297.	1.0	20
66	NAVA enhances tidal volume and diaphragmatic electro-myographic activity matching: a Range90 analysis of supply and demand. Journal of Clinical Monitoring and Computing, 2013, 27, 61-70.	0.7	25
67	Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Critical Care, 2012, 16, R14.	2.5	155
68	Electrical Vagus Nerve Stimulation and Nicotine Effects in Peritonitis-Induced Acute Lung Injury in Rats. Inflammation, 2011, 34, 29-35.	1.7	42
69	Neurally adjusted ventilatory assist improves patientâ€“ventilator interaction. Intensive Care Medicine, 2011, 37, 263-271.	3.9	199
70	Delayed colopericardial fistula and pyopneumopericardium. Intensive Care Medicine, 2010, 36, 557-558.	3.9	2
71	A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Critical Care, 2009, 13, R36.	2.5	33
72	Therapeutic dose of acetaminophen may be able to induce fulminant hepatitis in the presence of risk factors of hepatotoxicity. Report of two cases and short review. British Journal of Anaesthesia, 2009, 103, .	1.5	0

#	Article	IF	Citations
73	Influence of enrollment sequence effect on observed outcomes in the ADDRESS and PROWESS studies of drotrecogin alfa (activated) in patients with severe sepsis. Critical Care, 2008, 12, R117.	2.5	9
74	Severe community acquired pneumonia update: mortality, mechanisms and medical intervention. Critical Care, 2008, 12, S1.	2.5	9
75	Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition. Critical Care, 2008, 12, S4.	2.5	13
76	Progress in medical management of intra-abdominal infection. Current Opinion in Infectious Diseases, 2008, 21, 393-398.	1.3	12
77	ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: One-year safety and efficacy evaluation*. Critical Care Medicine, 2007, 35, 1457-1463.	0.4	38
78	Clinical trials in severe sepsis with drotrecogin alfa (activated). Critical Care, 2007, 11, S5.	2.5	29
79	International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety. Journal of Critical Care, 2007, 22, 142-152.	1.0	20
80	Pharmacological Inhibition of Tissue Factor. Seminars in Thrombosis and Hemostasis, 2006, 32, 071-076.	1.5	13
81	Compartmentalization of the protease-antiprotease balance in early severe acute pancreatitis. Suizo, 2006, 21, 99-101.	0.1	0
82	Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial *. Critical Care Medicine, 2004, 32, 2207-2218.	0.4	95
83	Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Medicine, 2003, 29, 894-903.	3.9	166
84	Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification. Critical Care, 2003, 7, 445.	2.5	20
85	Anticoagulant therapy in acute lung injury. Critical Care Medicine, 2003, 31, S329-S336.	0.4	87
86	Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. New England Journal of Medicine, 2001, 344, 699-709.	13.9	8,411
87	Recurrent postinfantile syncytial giant cell hepatitis after orthotopic liver transplantation. Transplant International, 1998, 11, 320-322.	0.8	13
88	Recurrent postinfantile syncytial giant cell hepatitis after orthotopic liver transplantation. Transplant International, 1998, 11, 320-322.	0.8	6
89	Adult liver transplantation and abnormalities of splanchnic veins: experience in 53 patients. Transplant International, 1997, 10, 125-132.	0.8	71
90	Adult liver transplantation and abnormalities of splanchnic veins: experience in 53 patients. Transplant International, 1997, 10, 125-132.	0.8	25